Susan Kenslow
Nurse Practitioner · West Plains, MONPI 1043361983
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,570 of the $2,234 with a category attached, or 70.3%. It is spread thinly across 32 manufacturers, the largest accounting for just 22.0%. Reporting peaked in 2022 at $978 and has fallen 87.6% since, to $122 in 2025.
Across 104 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$491
- Lilly USA, LLC$366
- Novartis$301
- Merck$184
- AbbVie$98
- Amgen$77
- plus $716 from 26 others
What the payments were for
- Food & beverage$1,57070%
- Education$66430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 14 | $491 |
| Lilly USA, LLC | 7 | $366 |
| Novartis | 18 | $301 |
| Merck | 11 | $184 |
| AbbVie | 5 | $98 |
| Amgen | 4 | $77 |
| AstraZeneca(2 entities) | 6 | $77 |
| Bristol Myers Squibb | 5 | $69 |
| Sanofi | 3 | $55 |
| Gilead | 3 | $49 |
| Pfizer | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $34 |
| Incyte Corporation | 2 | $29 |
| Ipsen Biopharmaceuticals, Inc | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Medtronic | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $16 |
| G1 Therapeutics, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $14 |
| GSK | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Bayer | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $10 |
How this compares
$2,234 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levofloxacin | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in West Plains
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
- Matthew BrunsBridgeton$126K
- Michelle DickensSpringfield$59K
- Robert HafnerKansas City$47K
- Tracey CarpenterChesterfield$47K
- Laura GrantSaint Charles$34K
- Courtney JefferyKansas City$24K
- Carrie Roth BettlachSaint Louis$21K
- Amanda HumbersFarmington$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.